24 March 2022
Kobi Ben Chitrit, Liron Hacohen and Nitzan Fischer Conforti represented Nucleai in its raising of $33 million in Round B jointly led by Section 32 and Sanofi Ventures. The company plans to use the new funding to further develop its drug discovery platform and expand its commercial operations to biopharmaceutical companies and contract research organizations.

Kobi Ben Chitrit, Liron Hacohen and Nitzan Fischer Conforti represented Nucleai in its raising of $33 million in Round B jointly led by Section 32 and Sanofi Ventures. The company plans to use the new funding to further develop its drug discovery platform and expand its commercial operations to biopharmaceutical companies and contract research organizations.


14 February 2022
Advs. Kobi Ben Chitrit, David Roness, Eyal Safrai and interns Aliza Haber Feld and Yaara Sari represented Technology-Driven Precision Medicine Company Variantyx in a series C-2 funding round, led by New Era Capital Partners.  This will be used to fuel company growth and launch newly developed solutions across all markets, with a focus on precision oncology.

Advs. Kobi Ben Chitrit, David Roness, Eyal Safrai and interns Aliza Haber Feld and Yaara Sari represented Technology-Driven Precision Medicine Company Variantyx in a series C-2 funding round, led by New Era Capital Partners.  This will be used to fuel company growth and launch newly developed solutions across all markets, with a focus on precision oncology.


19 November 2021
Advs. Daniel Green and Tali Har-Oz represented Oravax Medical, a joint venture established by Oramed Pharmaceuticals and Premas Biotech, in a strategic collaboration agreement with Genomma Lab Internacional whereby Genomma Lab would develop and commercialize Oravax’s oral COVID-19 vaccine in Mexico and drive business development in Latin America.

Advs. Daniel Green and Tali Har-Oz represented Oravax Medical, a joint venture established by Oramed Pharmaceuticals and Premas Biotech, in a strategic collaboration agreement with Genomma Lab Internacional whereby Genomma Lab would develop and commercialize Oravax’s oral COVID-19 vaccine in Mexico and drive business development in Latin America.


04 August 2021
Advs. Barry Levenfeld and Elan Loshinsky and intern Michael Portman represented the medical device company Append Medical, an Israeli company that has developed an implantable device designed to reduce stroke risk in those suffering from atrial fibrillation, in raising a $7.4 million Series A round. The round was led by an unnamed strategic company and MedTecX LP, as well as other investments matched by the Israel Innovation Authority. They will join current investors Boston Scientific, MEDX Ventures, and Intellectual Ventures.  

Advs. Barry Levenfeld and Elan Loshinsky and intern Michael Portman represented the medical device company Append Medical, an Israeli company that has developed an implantable device designed to reduce stroke risk in those suffering from atrial fibrillation, in raising a $7.4 million Series A round. The round was led by an unnamed strategic company and MedTecX LP, as well as other investments matched by the Israel Innovation Authority. They will join current investors Boston Scientific, MEDX Ventures, and Intellectual Ventures.

 


30 September 2020
Advs. Micki Shapira, Daniel Green and Sophy Litvin represented Fosun Health Fund (the venture capital arm of Fosun Pharma) in an exclusive license and supply agreement with Raziel Therapeutics to develop and commercialize Raziel's proprietary RZL-012, an injection used for reducing double chins, in mainland China, Hong Kong, Macau, and Taiwan for milestone payments of up to $74 million plus tiered royalties on future sales. The team was joined by advs. Miriam Friedmann, Inbar Hakimian-Nahari and intern Yang Cheng.

Advs. Micki Shapira, Daniel Green and Sophy Litvin represented Fosun Health Fund (the venture capital arm of Fosun Pharma) in an exclusive license and supply agreement with Raziel Therapeutics to develop and commercialize Raziel's proprietary RZL-012, an injection used for reducing double chins, in mainland China, Hong Kong, Macau, and Taiwan for milestone payments of up to $74 million plus tiered royalties on future sales. The team was joined by advs. Miriam Friedmann, Inbar Hakimian-Nahari and intern Yang Cheng.


21 July 2020
Advs. Ben Sandler and Barry Levenfeld represented orthologics company Bioventus in its investment in the Israeli medical device company Cartiheal, including in signing an option to buy it. Assisted alongside David Roness, Ofir Levy, Daniel Marcovici, Daniel Green, Eli Greenbaum, Guy Fuhrer, Miriam Friedmann, Shira Teger, Tali Har-Oz, Hadar Stein, Chaim Cohen, Chaya Alexandra Y.N. Kong, Sophy Litvin, Nir Kamhi, Ofir Paz, Shmuel Brill and interns Noah Levy, Katya Kagantsov and Danya Sakols.

Advs. Ben Sandler and Barry Levenfeld represented orthologics company Bioventus in its investment in the Israeli medical device company Cartiheal, including in signing an option to buy it. Assisted alongside David Roness, Ofir Levy, Daniel Marcovici, Daniel Green, Eli Greenbaum, Guy Fuhrer, Miriam Friedmann, Shira Teger, Tali Har-Oz, Hadar Stein, Chaim Cohen, Chaya Alexandra Y.N. Kong, Sophy Litvin, Nir Kamhi, Ofir Paz, Shmuel Brill and interns Noah Levy, Katya Kagantsov and Danya Sakols.


09 July 2020
Adv. Tamar Tavory recently joined our firm as special counsel and will be strengthening the firm’s digital health practice, with a particular focus on telehealth, AI in medicine, medical research, and secondary use of medical data.

Adv. Tamar Tavory recently joined our firm as special counsel and will be strengthening the firm’s digital health practice, with a particular focus on telehealth, AI in medicine, medical research, and secondary use of medical data.


02 July 2020
Advs. Barry Levenfeld, Adrian Daniels, Noah Zivan, Vered Glaubach and intern Nitzan Bigman represented Barclays in their role as underwriters in the IPO of clinical-stage bio-pharmaceutical company PolyPid on Nasdaq, in which $60 million were raised. They were joined by Shira Lahat, Daniel Green, Miriam Friedmann, Sophy Litvin, Dr. Eran Lempert, Assaf Mesica and Shai Margalit.

Advs. Barry Levenfeld, Adrian Daniels, Noah Zivan, Vered Glaubach and intern Nitzan Bigman represented Barclays in their role as underwriters in the IPO of clinical-stage bio-pharmaceutical company PolyPid on Nasdaq, in which $60 million were raised. They were joined by Shira Lahat, Daniel Green, Miriam Friedmann, Sophy Litvin, Dr. Eran Lempert, Assaf Mesica and Shai Margalit.


14 June 2020
Advs. Simon Weintraub, Daniel Green, Shira Teger and Tali Har-Oz represented Prilenia Therapeutics in a Series A financing round in which it raised 62.5 million dollars. The new funds will be used for two late-stage trials, which could lead to the registration of pridopidine for the treatment of HD and ALS.

Advs. Simon Weintraub, Daniel Green, Shira Teger and Tali Har-Oz represented Prilenia Therapeutics in a Series A financing round in which it raised 62.5 million dollars. The new funds will be used for two late-stage trials, which could lead to the registration of pridopidine for the treatment of HD and ALS.


17 March 2019
Advs. Barry Levenfeld, Ben Sandler, Evan Schendler, Alona Toledano, Ofir Levy, Shay Fahima, Yoheved Novogroder Shoshan, Daniel Green, Miriam Friedmann, Tali Har-Oz and the interns Itamar Ben David, Hadar Stein and Elad Cohen represented the med-tech giant Stryker in the acquisition of Orthospace Ltd, an Israeli company that has developed a device for treating serious shoulder pain, for $220 million. 

Advs. Barry Levenfeld, Ben Sandler, Evan Schendler, Alona Toledano, Ofir Levy, Shay Fahima, Yoheved Novogroder Shoshan, Daniel Green, Miriam Friedmann, Tali Har-Oz and the interns Itamar Ben David, Hadar Stein and Elad Cohen represented the med-tech giant Stryker in the acquisition of Orthospace Ltd, an Israeli company that has developed a device for treating serious shoulder pain, for $220 million. 


Pages

Recognition

Subscribe for updates and news